These results clearly indicated that the regionally selective induction of CYP1A2, together with its differential catalytic ability to oxidize BR, may explain the lower sensitivity to BR toxicity of the COR compared with the CLL. The gene discussed is CYP1A2; the disease is B-cell chronic lymphocytic leukemia.